Skip to main content
SpringerLink
Log in

Hematopoietic Stem Cell Transplantation in Patients with Inborn Errors of Immunity and Malignancy

  • Chapter
  • First Online:
Cancer Research: An Interdisciplinary Approach

Part of the book series: Interdisciplinary Cancer Research ((ICR,volume 1))

Abstract

The number of inborn errors of immunity (IEI) identified due to monogenic mutations has rapidly increased with the genomic revolution. Affected patients have an increased risk of developing malignancy compared to the normal population. The treatment of these malignancies is challenging due to the underlying diseases themselves and associated co-morbidities.

Outcome of hematopoietic stem cell transplantation (HSCT) for patients with IEI has dramatically improved in the last 10–15 years, both in terms of survival and long-term good quality of immune reconstitution leading to improved quality of life. It is important to identify patients with IEI who have a malignancy to direct treatment of the malignancy itself appropriately and the approach to HSCT. A successful outcome can be achieved even in these patients with a multi-disciplinary team including Immunologists, Oncologists and transplanters. Many patients with IEI may benefit from pre-emptive HSCT to decrease the risk of malignancy or if they have had a previously treated malignancy, HSCT may reduce the risk of a second malignancy.

This review will outline successes in the field of HSCT for IEI, and specifically consider HSCT in the context of treatment and prevention of malignancy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Albert MH, Slatter MA, Gennery AR et al (2022a) Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT Inborn Errors Working Party analysis. Blood 139:2066–2079

    CAS  PubMed  Google Scholar 

  • Albert MH, Sirait T, Eikema DJ et al. (2022b) Hematopoietic stem cell transplantation for adolescents and adults with inborn errors of immunity, an EBMT IEWP study. Blood: blood.2022015506. https://doi.org/10.1182/blood.2022015506. Online ahead of print

  • Aydin SE, Kilic SS, Aytekin C et al (2015) Inborn errors working party of EBMT. DOCK8 deficiency: clinical and immunological phenotype and treatment options – a review of 136 patients. J Clin Immunol 35:189–198

    CAS  PubMed  Google Scholar 

  • Aydin SE, Freeman AF, Al-Herz W et al (2019) Hematopoietic stem cell transplantation as treatment for patients with DOCK8 deficiency. J Allergy Clin Immunol Pract 7:848–855

    PubMed  Google Scholar 

  • Bach FH, Albertini RJ, Joo P et al (1968) Bone marrow transplantation in a patient with the Wiskott-Aldrich syndrome. Lancet 2(7583):1364e6

    Google Scholar 

  • Bartelink IH, Lalmohamed A, van Reij EM et al (2016) Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. Lancet Haematol 3:e526–e536

    PubMed  PubMed Central  Google Scholar 

  • Bomken S, van der Werff Ten Bosch J, Attarbaschi A et al (2018) Current understanding and future research priorities in malignancy associated with inborn errors of immunity and DNA repair disorders: The Perspective of an Interdisciplinary Working Group. Front Immunol 9:2912

    CAS  PubMed  PubMed Central  Google Scholar 

  • Booth C, Gilmour KC, Veys P et al (2011) X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease. Blood 117:53–62

    CAS  PubMed  PubMed Central  Google Scholar 

  • Burroughs LM, Petrovic A, Brazauskas R et al (2020) Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report. Blood 135:2094–2105

    PubMed  PubMed Central  Google Scholar 

  • Chandra S, Chandrakasan S, Dávila Saldaña BJ et al (2021) Experience with a reduced toxicity allogeneic transplant regimen for non-CGD primary immune deficiencies requiring myeloablation. J Clin Immunol 41:89–98

    CAS  PubMed  Google Scholar 

  • Chiesa R, Wang J, Blok HJ et al (2020) Hematopoietic cell transplantation in chronic granulomatous disease: a study of 712 children and adults. Blood 136:1201–1211

    PubMed  Google Scholar 

  • Corbacioglu S, Topaloglu O, Aggarwal S (2022) A systematic review and meta-analysis of studies of defibrotide prophylaxis for veno-occlusive disease/sinusoidal obstruction syndrome. Clin Drug Investig 42(6):465–476

    CAS  PubMed  PubMed Central  Google Scholar 

  • Davrandi M, Harris S, Smith PJ et al (2022) The relationship between mucosal microbiota, colitis, and systemic inflammation in chronic granulomatous disorder. J Clin Immunol 42:312–324

    CAS  PubMed  Google Scholar 

  • De Koning J, Van Bekkum DW, Dicke KA et al (1969) Transplantation of bone-marrow cells and fetal thymus in an infant with lymphopenic immunological deficiency. Lancet 1:1223–1227

    PubMed  Google Scholar 

  • Dunaikina M, Zhekhovtsova Z, Shelikhova L et al (2021) Safety and efficacy of the low-dose memory (CD45RA-depleted) donor lymphocyte infusion in recipients of αβ T cell-depleted haploidentical grafts: results of a prospective randomized trial in high-risk childhood leukemia. Bone Marrow Transplant 56:1614–1624

    CAS  PubMed  Google Scholar 

  • Eftychidis I, Sakellari I, Anagnostopoulos A, Gavriilaki E (2021) Endothelial dysfunction and vascular complications after allogeneic hematopoietic cell transplantation: an expert analysis. Expert Rev Hematol 14:831–840

    CAS  PubMed  Google Scholar 

  • Ezoe S (2012) Secondary leukemia associated with the anti-cancer agent, etoposide, a topoisomerase II inhibitor. Int J Environ Res Public Health 9:2444–2453

    CAS  PubMed  PubMed Central  Google Scholar 

  • Ferrua F, Galimberti S, Courteille V et al (2019) Hematopoietic stem cell transplantation for CD40 ligand deficiency: results from an EBMT/ESID-IEWP-SCETIDE-PIDTC study. J Allergy Clin Immunol 143:2238–2253

    CAS  PubMed  Google Scholar 

  • Gatti RA, Meuwissen HJ, Allen HD et al (1968) Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet 2(7583):1366e9

    Google Scholar 

  • Ghosh S, Drexler I, Bhatia S et al (2018) Interleukin-2-inducible T-cell kinase deficiency-new patients, new insight? Front Immunol 9:979

    PubMed  PubMed Central  Google Scholar 

  • Ghosh S, Köstel Bal S, Edwards ESJ et al (2020) Extended clinical and immunological phenotype and transplant outcome in CD27 and CD70 deficiency. Blood 136:2638–2655

    PubMed  PubMed Central  Google Scholar 

  • Goldschmidt MH, Kennedy JS, Kennedy DR et al (2006) Severe papillomavirus infection progressing to metastatic squamous cell carcinoma in bone marrow-transplanted X-linked SCID dogs. J Virol 80:6621–6628

    CAS  PubMed  PubMed Central  Google Scholar 

  • Groll AH, Pana D, Lanternier F et al (2021) 8th European conference on infections in leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-hematopoietic cell transplantation. Lancet Oncol 22:e254–e269

    PubMed  Google Scholar 

  • Haddad E, Logan BR, Griffith LM et al (2018) SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery. Blood 132:1737–1749

    CAS  PubMed  PubMed Central  Google Scholar 

  • Hauck F, Voss R, Urban C, Seidel MG (2018) Intrinsic and extrinsic causes of malignancies in patients with primary immunodeficiency disorders. J Allergy Clin Immunol 141:59–68.e4

    PubMed  Google Scholar 

  • Ivana T, Robert P, Pavel S et al (2022) Cytomegalovirus and other herpesviruses after hematopoietic cell and solid organ transplantation: From antiviral drugs to virus-specific T cells. Transpl Immunol 71:101539

    CAS  PubMed  Google Scholar 

  • Jonkman-Berk BM, van den Berg JM, Ten Berge IJ et al (2015) Primary immunodeficiencies in the Netherlands: national patient data demonstrate the increased risk of malignancy. Clin Immunol 156:154–162

    CAS  PubMed  Google Scholar 

  • Kesserwan C, Sokolic R, Cowen EW et al (2012) Multicentric dermatofibrosarcoma protuberans in patients with adenosine deaminase-deficient severe combined immune deficiency. J Allergy Clin Immunol 129:762–769.e761

    CAS  PubMed  Google Scholar 

  • Kitko CL, Abdel-Azim H, Carpenter PA et al (2022) A prospective, multicenter study of closed-system extracorporeal photopheresis for children with steroid-refractory acute graft-versus-host disease. Transplant Cell Ther 28:261.e1–261.e7

    CAS  PubMed  Google Scholar 

  • Laberko A, Gennery AR (2018) Clinical considerations in the hematopoietic stem cell transplant management of primary immunodeficiencies. Expert Rev Clin Immunol 14:297–306

    CAS  PubMed  Google Scholar 

  • Lane JP, Stewart CJ, Cummings SP, Gennery AR (2016) Functional changes in gut microbiota during hematopoietic stem cell transplantation for severe combined immunodeficiency. J Allergy Clin Immunol 138:622–625.e3

    PubMed  Google Scholar 

  • Lankester AC, Neven B, Mahlaoui N et al (2022) Hematopoietic cell transplantation in severe combined immunodeficiency: the SCETIDE 2006-2014 European cohort. J Allergy Clin Immunol 149:1744–1754.e8

    CAS  PubMed  Google Scholar 

  • Leiding JW, Okada S, Hagin D et al (2018) Hematopoietic stem cell transplantation in patients with gain-of-function signal transducer and activator of transcription 1 mutations. J Allergy Clin Immunol 141:704–717.e5

    CAS  PubMed  Google Scholar 

  • Lum SH, Greener S, Perez-Heras I et al (2022) T-replete HLA-matched grafts vs T-depleted HLA-mismatched grafts in inborn errors of immunity. Blood Adv 6:1319–1328

    CAS  PubMed  PubMed Central  Google Scholar 

  • Lutz M, Mielke S (2016) New perspectives on the use of mTOR inhibitors in allogeneic hematopoietic stem cell transplantation and graft-versus-host disease. Br J Clin Pharmacol 82:1171–1179

    CAS  PubMed  PubMed Central  Google Scholar 

  • Marsh RA, Bleesing JJ, Chandrakasan S et al (2014) Reduced-intensity conditioning hematopoietic cell transplantation is an effective treatment for patients with SLAM-associated protein deficiency/X-linked lymphoproliferative disease type 1. Biol Blood Marrow Transplant 20:1641–1645

    CAS  PubMed  Google Scholar 

  • Marsh RA, Leiding JW, Logan BR et al (2019) Chronic granulomatous disease-associated IBD resolves and does not adversely impact survival following allogeneic HCT. J Clin Immunol 39:653–667

    PubMed  PubMed Central  Google Scholar 

  • Mayor PC, Eng KH, Singel KL et al (2018) Cancer in primary immunodeficiency diseases: cancer incidence in the United States Immune Deficiency Network Registry. J Allergy Clin Immunol 141:1028–1035

    PubMed  Google Scholar 

  • McCarthy KL, Playford EG, Looke DF, Whitby M (2007) Severe photosensitivity causing multifocal squamous cell carcinomas secondary to prolonged voriconazole therapy. Clin Infect Dis 44:e55–e56

    CAS  PubMed  Google Scholar 

  • Moratto D, Giliani S, Bonfim C et al (2011) Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980–2009: an international collaborative study. Blood 118:1675–1684

    CAS  PubMed  PubMed Central  Google Scholar 

  • Otto WR, Green A (2022) Antiviral therapeutics in pediatric transplant recipients. Infect Dis Clin N Am 36:125–146

    Google Scholar 

  • Prunotto G, Offor UT, Samarasinghe S et al (2020) HSCT provides effective treatment for lymphoproliferative disorders in children with primary immunodeficiency. J Allergy Clin Immunol 146:447–450

    CAS  PubMed  Google Scholar 

  • Rao K, Amrolia PJ, Jones A et al (2005) Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen. Blood 105:879–885

    CAS  PubMed  Google Scholar 

  • Rigoni R, Fontana E, Dobbs K et al (2020) Cutaneous barrier leakage and gut inflammation drive skin disease in Omenn syndrome. J Allergy Clin Immunol 146:1165–1179.e11

    CAS  PubMed  PubMed Central  Google Scholar 

  • Salavoura K, Kolialexi A, Tsangaris G, Mavrou A (2008) Development of cancer in patients with primary immunodeficiencies. Anticancer Res 28:1263–1269

    PubMed  Google Scholar 

  • Slack J, Albert MH, Balashov D et al (2018) Outcome of hematopoietic cell transplantation for DNA double-strand break repair disorders. J Allergy Clin Immunol 141:322–328.e10

    CAS  PubMed  Google Scholar 

  • Slatter MA, Gennery AR (2021) Treosulfan-based conditioning for inborn errors of immunity. Ther Adv Hematol 12:20406207211013985

    CAS  PubMed  PubMed Central  Google Scholar 

  • Slatter MA, Rao K, Abd Hamid IJ et al (2018) Treosulfan and fludarabine conditioning for hematopoietic stem cell transplantation in children with primary immunodeficiency: UK experience. Biol Blood Marrow Transplant 24:529–536

    CAS  PubMed  Google Scholar 

  • Straathof KC, Rao K, Eyrich M et al (2009) Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study. Lancet 374:912–920

    CAS  PubMed  Google Scholar 

  • Tangye SG, Al-Herz W, Bousfiha A et al (2020) Human inborn errors of immunity: 2019 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol 40:24–64

    PubMed  PubMed Central  Google Scholar 

  • Tesch VK, Abolhassani H, Shadur B et al (2020) Long-term outcome of LRBA deficiency in 76 patients after various treatment modalities as evaluated by the immune deficiency and dysregulation activity (IDDA) score. J Allergy Clin Immunol 145:1452–1463

    CAS  PubMed  Google Scholar 

  • Unni MNM, Elfeky R, Rao K et al (2018) Non-posttransplant lymphoproliferative disorder malignancy after hematopoietic stem cell transplantation in patients with primary immunodeficiency: UK experience. J Allergy Clin Immunol 141:2319-21 e1

    Google Scholar 

  • Wojenski DJ, Bartoo GT, Merten JA et al (2015) Voriconazole exposure and the risk of cutaneous squamous cell carcinoma in allogeneic hematopoietic stem cell transplant patients. Transpl Infect Dis 17:250–258

    CAS  PubMed  Google Scholar 

  • Wolska-Kusnierz B, Pastorczak A, Fendler W et al (2021) Hematopoietic stem cell transplantation positively affects the natural history of cancer in Nijmegen Breakage syndrome. Clin Cancer Res 27:575–584

    PubMed  Google Scholar 

  • Yamamoto ML, Maier I, Dang AT et al (2013) Intestinal bacteria modify lymphoma incidence and latency by affecting systemic inflammatory state, oxidative stress, and leukocyte genotoxicity. Cancer Res 73:4222–4232

    CAS  PubMed  PubMed Central  Google Scholar 

  • Zeiser R, Polverelli N, Ram R et al (2021) Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease. N Engl J Med 385:228–238

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

No acknowledgements.

Author information

Authors and Affiliations

  1. Paediatric Hematopoietic Stem Cell Transplant Unit, Great North Children’s Hospital, Newcastle upon Tyne, UK

    Andrew R. Gennery & Mary A. Slatter

  2. Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK

    Andrew R. Gennery & Mary A. Slatter

Authors
  1. Andrew R. Gennery
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mary A. Slatter
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mary A. Slatter .

Editor information

Editors and Affiliations

  1. Cancer Immunology Project (CIP), Universal Scientific Education and Research Network (USERN), Stockholm, Sweden

    Nima Rezaei

Ethics declarations

Not relevant for this article.

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Gennery, A.R., Slatter, M.A. (2022). Hematopoietic Stem Cell Transplantation in Patients with Inborn Errors of Immunity and Malignancy. In: Rezaei, N. (eds) Cancer Research: An Interdisciplinary Approach. Interdisciplinary Cancer Research, vol 1. Springer, Cham. https://doi.org/10.1007/16833_2022_50

Download citation

Publish with us

Policies and ethics

Search

Navigation